Abstract: The present application provides the preparation and use of a 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride. According to the present application, a 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride is directly synthesized by a one-step reaction, and the compound includes a pharmaceutically acceptable salt thereof. 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride has been proved to have a good antiparkinsonian activity by animal tests, and it is a class of novel antiparkinsonian drug candidates.

Abstract: A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6 alkyl; and R4 is selected from hydrogen, C1-6 alkyl and a group as described for R2; characterised in that R2 is selected from groups (i) —CONH—R5 (ii) —CH2NHCO—R5 (iii) —SO2NH—R5 (iv) —CH2NHSO2—R5 (v) —CR6R6OR7 (viii) —CONHCOR5  wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-3 alkyl, aryl and C7-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7

Abstract: A compound of formula I wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, and R3 is selected from hydrogen and C1-6 alkyl; characterized in that R2 is selected from groups (i) —CONH—R5 (ii)—CR6R6OR7 (iii) —CONHCOR5 and (iv) —CON(CnH2n+1)2 R4 is selected from hydrogen, C1-6 alkyl and a group as described for R2; R5 is selected from hydrogen and optionally hydroxy, alkoxy, aryloxy or aralkoxy substituted C1-13 alkyl, aryl and C7-13 alkyl R6 is independently selected from hydrogen and C1-13 alkyl, R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound and CnH2n+1 is C1-6alkyl with the proviso that the compound

Abstract: A novel 3-hydroxypyridinone compound of formula I is provided 1

Abstract: A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6alkyl; and R4 is selected from hydrogen, C1-6alkyl and a group as described for R2; characterised in that R2 is selected from groups —CONH—R5  (i) —CH2NHCO—R5  (ii) —SO2NH—R5  (iii) —CH2NHSO2—R5  (iv) —CR6R6OR7  (v) —CONHCOR5  (viii)  wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-13 alkyl, aryl and C71-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl,